Silence Therapeutics to Present at Guggenheim's Genomic Medicines and Rare Disease Days

Author's Avatar
Mar 29, 2023

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Company management will participate in a virtual fireside chat at Guggenheim’s Genomic Medicines and Rare Disease Days on Tuesday April4that 2:10 p.m. ET.